linjc16/ctgov huggingface dataset:
Nutrition Day in Hospitals, Nursing Homes and Community. Israel January 2010

Study Overview
=================
Brief Summary
-----------------
This study is a one-day international cross-sectional nutritional audit in one ward. The purpose of this study is to generate a risk and level of nutritional intervention profile for an individual unit/ward based on case-mix, structures and social environment.

Conditions
-----------------
Nutritional Status

Intervention / Treatment
-----------------
* Other: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A adult patients within the unit from 7H00 to 7H00 Exclusion Criteria: Patients younger than 18 years Patients admitted and discharged during same calendar day

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ward population<br>Patients hospitalized in the Orthopedics B Ward in the Hillel Yaffe Medical Center that choose to participate in the study | Other: No Intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nutritional status of ward patients and hospitalization outcome
IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer

Study Overview
=================
Brief Summary
-----------------
Change of IL-6 and IL-8 level in blood and pleural effusion before and after chemotherapy correlate with the prognosis of the disease

Detailed Description
-----------------
To assess the correlation between the disease prognosis and the level of IL-6 and IL-8 in blood and pleural effusion before and after chemotherapy in patients with metastatic breast cancer

Official Title
-----------------
A Prospective Study Assessing the Correlation Between Disease Prognosis and the Level of IL-6 and IL-8 Level in Blood and Pleural Effusion Before and After Chemotherapy in Patients With Metastatic Breast Cancer

Conditions
-----------------
Metastatic Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female between 18 and 70 years old; Patients with histologic proved metastatic breast cancer; Pleural effusion with the volume of more than 1000ml, as documented by CT, X ray or ultrasound; There are no other diseases which cause the elevation of IL-6 or IL-8, such as cirrhosis of liver, anaphylactoid purpura, acute pancreatitis; With at least one measurable disease according to RECIST criteria, Normal laboratory results:ANC≥2.0×109/L,Hb≥80g/L,plt≥100×109/L,TB<UNL (<1.5 x UNL in patients with liver mets),ALT/AST< 1.5 x UNL (<2.5x UNL in patients with liver mets),AKP<5 x UNL(except bone mets),Cr<UNL; Normal functions with heart, liver,renal and bone marrow; Got ICF before enrollment; Life expectancy more than 12 weeks. Exclusion Criteria: Pregnant or breast-feeding women or positive serum pregnancy test; Uncontrolled brain metastases; No recovery from previous radiation or accepted radiation within 4 weeks before enrollment; Participation in any investigational drug study within 4 weeks preceding treatment start; Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin; Serious uncontrolled intercurrent infections; Poor compliance.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pleural effusion<br>patients with pleural effusion | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| level of IL-6 and IL-8 |  | 2 days |
Ultrasonography in Predicting Difficult Intubation in Obese Emergency Surgical Patients

Study Overview
=================
Brief Summary
-----------------
Validity of ultrasonography in predicting difficult laryngoscopy and confirming endotracheal intubation in obese emergency surgical patients

Detailed Description
-----------------
The aim of the study is to determine whether preoperative ultrasound assessment of of the upper airway can predict difficult laryngscopy in emergency surgical obese patients , by analysis correlations between ultrasound measurements of anterior cervical soft in the upper airway, and the Cormack-Lehane grade. And evaluate its role in confirming the endotracheal placement The secondary objective was to determine whether clinical screening tests are independent predictors of difficult airway.

Official Title
-----------------
Validity of Ultrasonography in Predicting Difficult Laryngoscopy and Confirming Endotracheal Intubation in Obese Emergency Surgical Patients

Conditions
-----------------
Preoperative Ultrasound Assessment of the Upper Airway Can Predict Difficult Laryngscopy in Obese at Emergency Operations

Intervention / Treatment
-----------------
* Device: ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult obese patients (BMI>35) of both sex aged from 18 to 60 years undergoing urgent surgeries under general anasthesia with tracheal intubation. Exclusion Criteria: . Patients with removable upper dentures, upper airway pathology, cervical spine fractures, full stomach, maxillofacial trauma or unstable patients and pregnant women will be excluded from the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: ultrasound|using of ultrasound in prediction of difficult intubation in obese surgical patients|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prediction of difficult intubation in obese emergency surgical patients by ultrasound | determine whether preoperative ultrasound assessment of of the upper airway can predict difficult laryngscopy in emergency surgical obese patients , by analysis correlations between ultrasound measurements of anterior cervical soft in the upper airway, and the Cormack-Lehane grade. And evaluate its role in confirming the endotracheal placement | 30minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ultrasound _difficult intubation _obese _emergency operations
Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

Study Overview
=================
Brief Summary
-----------------
The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and PH phenotype.

Official Title
-----------------
Acute Hemodynamic Comparison of Inhaled Nitric Oxide and Inhaled Epoprostenol in Pulmonary Hypertension

Conditions
-----------------
Pulmonary Hypertension

Intervention / Treatment
-----------------
* Drug: Vasodilator testing (Inhaled Nitric Oxide)
* Drug: Vasodilator testing (Inhaled Epoprostenol)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mPAP ≥ 21mmHg, PAWP ≤ 25mmHg, and PVR ≥3 WU Classified as WHO group I-III pulmonary hypertension Exclusion Criteria: WHO group IV and V pulmonary hypertension Patients who are on baseline pulmonary vasodilator medications Severe aortic or mitral valve disease Patients who are pregnant Left ventricular ejection fraction of <35% Patients who are hospitalized as inpatients at the time of RHC Patients with systolic blood pressure <90mmHg or mean arterial pressure of < 60mmHg

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Inhaled Nitric Oxide<br>Vasodilator testing will be performed with inhaled nitric oxide | Drug: Vasodilator testing (Inhaled Nitric Oxide)<br>* Right heart catheterization with vasodilator testing with each arms' associated agent will be performed<br>|
| Experimental: Inhaled Epoprostenol<br>Vasodilator testing will be performed with inhaled epoprostenol | Drug: Vasodilator testing (Inhaled Epoprostenol)<br>* Right heart catheterization with vasodilator testing with each arms' associated agent will be performed<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in mean pulmonary artery pressure | The primary outcome will be change in mean pulmonary artery pressure (mmHg) from baseline to after 5-minutes of inhaled vasodilator. | Pre-pulmonary vasodilator testing measurements (baseline) will be compared to post-pulmonary vasodilator testing measurements during diagnostic right heart catheterization. |
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to study: Effects of arzoxifene on bone fractures and bone mass. Effects of arzoxifene on getting breast cancer. Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke. Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health. Effects of arzoxifene on the uterus. The safety of arzoxifene and any side effects.

Official Title
-----------------
Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women With Osteoporosis or With Low Bone Density.

Conditions
-----------------
Osteoporosis, Postmenopausal

Intervention / Treatment
-----------------
* Drug: Arzoxifene
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 60-85 years of age Female At least two years since last menstrual cycle Exclusion Criteria: Abnormal or unexplained vaginal bleeding. Bone disorders, other than osteoporosis or low bone mass History of breast cancer, cancer of the uterus, or any cancer in the last five years (except skin cancer). History of cerebral vascular accidents or venous thromboembolic events Medications outlined

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: Arzoxifene<br>* 20mg, oral, tablet, once a day for 36 months<br>* Other names: LY353381;|
| Placebo Comparator: 2<br> | Drug: Placebo<br>* oral, tablet, once a day for 36 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effects of arzoxifene on bone fractures and bone mass |  | 5 years | 
| Effects of arzoxifene on getting breast cancer |  | 5 years | 
| The safety of arzoxifene and any side effects |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effects of arzoxifene on certain types of cardiovascular events |  | 5 years | 
| Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health |  | 5 years | 
| Effects of arzoxifene on the uterus |  | 5 years | 
| Effects of arzoxifene on cognition |  | 5 years | 
| Effects of arzoxifene on back pain |  | 5 years |
Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects

Study Overview
=================
Brief Summary
-----------------
To Compare Pharmacokinetic and Pharmacodynamic Profiles of BEPO-A and REPO-A in Healthy Male Subjects

Detailed Description
-----------------
To Compare Pharmacokinetic and Pharmacodynamic Profiles of EPO (BEPO-A (4000 IU)) and EPO (REPO-A (4000 IU)) in Healthy Male Subjects

Official Title
-----------------
A Randomized, Open Label, Single-dose 2x2 Crossover Study to Compare Pharmacokinetic, Pharmacodynamic Profiles, and Tolerability of EPO (BEPO-A (4000 IU)) and EPO (REPO-A (4000 IU)) in Healthy Male Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: BEPO-A
* Drug: REPO-A


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Agree to all the purposes of the study by signing and dating the Informed Consent; Male, aged between 19 and 40 years, clinically healthy; BMI between 19 and 28; 90 mmHg ≤ SBP <140 mmHg, 50 mmHg ≤ DBP < 85 mmHg Exclusion Criteria: Hemoglobin <13 g / dL Ferritin <20 ng/mL or TIBC > 360 ug/ dL Vitamin B12 < 200 pg/mL or floate < 4 ng/mL %reticulpcyte > 3% platelet < 100,000/ul or > 400,000/ul GFR < 60mL/min/1.73m2 Going to or during treatment of the tumor Clinical history of allergy of biological products derived from mammalian albumin or any component of the formulation Clinical history of autoimmune or hereditary anemia A Positive reaction in the nicotine tests Principal Investigator of the study criteria.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BEPO-A<br>Single subcutaneous injection of BEPO-A 4000 IU (Bioreactor manufacturing process) | Drug: BEPO-A<br>* BEPO-A (Bioreactor manufacturing process)<br>|
| Active Comparator: REPO-A<br>Single subcutaneous injection of REPO-A 4000 IU (Roller bottle manufacturing process) | Drug: REPO-A<br>* REPO-A (Roller bottle manufacturing process)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cmax and AUClast |  | 1D before dosing, 1h, 2, 4h, 7h, 10h,12h, 14h, 2D 0h, 2D 8h, 3D 0h, 4D 0h, 5D 0h, 6D 0h, | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCinf, Tmax, t1/2β, CL/F, MRTinf (mean residence time) of Erythropoietin |  | 1D before dosing, 1h, 2, 4h, 7h, 10h,12h, 14h, 2D 0h, 2D 8h, 3D 0h, 4D 0h, 5D 0h, 6D 0h, |
Muscle Relaxation Therapy With Odorant Cue

Study Overview
=================
Brief Summary
-----------------
A novel procedure for generalized anxiety disorder where an odorant cue is paired with the state of deep relaxation during training. It is hypothesized that by smelling the odor in an anxiety-provoking situation, the patient will more easily invoke a state of relaxation, providing greater relief from the distressing tension and worry that characterize GAD.

Detailed Description
-----------------
We hypothesize that by presenting a novel odor to a patient in a state of deep relaxation, the odor will serve as a conditioned inhibitory stimulus, or safety signal, in anxiety-provoking situations. With the odor serving as a contextual cue for the state of relaxation.

Official Title
-----------------
A Study of Enhancement of Progressive Muscle Relaxation Therapy for Generalized Anxiety Disorder Through Use Of An Odorant Cue.

Conditions
-----------------
Generalized Anxiety Disorder, Anxiety

Intervention / Treatment
-----------------
* Behavioral: Odorant Cue


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: GAD without a comorbid active major psychiatric disorder. GAD must be the primary active psychiatric disorder. GAD determined via the Mini International Neuropsychiatric Interview (MINI). Exclusion Criteria: Significant medical illness that might interfere with the relaxation therapy or with training using the odorant. Actively abusing alcohol. Illicit substances. Currently using rapid-acting anxiolytic agents (e.g. benzodiazepines, hydroxyzine). Started an antidepressant, antipsychotic or mood stabilizing agent within three months of screening visit.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Odorant Cue|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PSWQ |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HAM-A |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anxiety, Mental Health
Outcomes Using MARS for Patients With ALF

Study Overview
=================
Brief Summary
-----------------
Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures.

Detailed Description
-----------------
Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures. Patient's charts will be accessed on EPIC by the PI or delegated study personnel. The investigator's anticipate completion of this study by January 31, 2022.

Official Title
-----------------
Outcomes Using MARS: A Single Center Experience

Conditions
-----------------
Alcoholic Hepatitis, Acute Liver Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • The patient was diagnosed with: Alcoholic hepatitis; AoCLF; OR Acute fulminant liver failure • The patient underwent at least one round of dialysis using plasma exchange or MARSTM Exclusion Criteria: Patient not meeting the inclusion criteria will be excluded. All patients who underwent MARS at MDMC will be included in the study population.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Transplant free survival mortality | transplant will be measured by date of death, and discharge | Rate at 30 days | 
| Difference in Demographics | co-morbidities, etiology of liver failure between those treated with MARS vs. controls | Rate at 30 days | 
| Improvement in Transplant | Determine whether treatment with MARS can help facilitate improvement in HE, LOS, and ICU duration. | Rate at 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographics | age (years), gender (male/female), race (Caucasian, black, Hispanic, Asian, other), BMI (kg/m2) | January 1, 2019 to January 31, 2022 | 
| Hepatorenal syndrome | Y/N | (in hospital [date of death or discharge or transplant]) and at 30 days | 
| Need for vasopressor support | Y/N | (in hospital [date of death or discharge or transplant]) and at 30 days | 
| Sepsis (as measured by by QSOFA criteria): | Y/N | (in hospital [date of death or discharge or transplant]) and at 30 days | 
| Need for CRRT as documented in the chart: | Y/N | (in hospital [date of death or discharge or transplant]) and at 30 days | 
| ICU duration | days of date of ICU duration | date of ICU admission and date of discharge (or death) | 
| long term dialysis | Need for long term dialysis (Y/N) | (in hospital [date of death or discharge or transplant]) and at 30 days |